Market Research Logo

Herpes Zoster (Shingles) - Pipeline Review, H2 2015

Herpes Zoster (Shingles) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Herpes Zoster (Shingles) - Pipeline Review, H2 2015’, provides an overview of the Herpes Zoster (Shingles)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Herpes Zoster (Shingles), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Zoster (Shingles) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Herpes Zoster (Shingles) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Herpes Zoster (Shingles) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Herpes Zoster (Shingles) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Herpes Zoster (Shingles)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Herpes Zoster (Shingles) Overview
Therapeutics Development
Pipeline Products for Herpes Zoster (Shingles) - Overview
Pipeline Products for Herpes Zoster (Shingles) - Comparative Analysis
Herpes Zoster (Shingles) - Therapeutics under Development by Companies
Herpes Zoster (Shingles) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Herpes Zoster (Shingles) - Products under Development by Companies
Herpes Zoster (Shingles) - Companies Involved in Therapeutics Development
Astellas Pharma Inc.
Beijing Minhai Biotechnology Co., Ltd
Epiphany Biosciences, Inc.
Foamix Pharmaceuticals Ltd.
GlaxoSmithKline Plc
Merck & Co., Inc.
NAL Pharmaceuticals Ltd.
Spider Biotech
TSRL, Inc.
Herpes Zoster (Shingles) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
acyclovir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
amenamevir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FV-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-1437173A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
herpes zoster vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NAL-3221 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NAL-3223 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SB-105A10 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TSR-087 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V-212 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
valomaciclovir stearate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Herpes Zoster (Shingles) - Recent Pipeline Updates
Herpes Zoster (Shingles) - Dormant Projects
Herpes Zoster (Shingles) - Discontinued Products
Herpes Zoster (Shingles) - Product Development Milestones
Featured News & Press Releases
Aug 03, 2015: ContraVir Pharmaceuticals Enrolls First Patient in Pivotal Phase 3 Study of FV-100 for Treatment of Shingles and Shingles-Associated Pain
Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial
Apr 28, 2015: GSK candidate vaccine for the prevention of shingles demonstrates overall efficacy of 97.2% which does not diminish in the age groups studied
Mar 09, 2015: ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN
Dec 18, 2014: Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint
Dec 18, 2014: Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant
Dec 09, 2014: ContraVir Pharmaceuticals Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles
Oct 16, 2014: ContraVir Pharmaceuticals Selects Pharmaceutical Product Development to Manage Phase 2b Study of Lead Antiviral FV-100 for Treating Shingles
Apr 09, 2013: Zoster Vaccine Effective Against Incident Herpes Zoster and Post-herpetic Neuralgia in Older US Population, Cohort Study Finds
Jul 18, 2012: Agenus Announces Initiation of Phase III Clinical Trial of GSK's Herpes Zoster Vaccine Candidate in Immunocompromised Patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Herpes Zoster (Shingles), H2 2015
Number of Products under Development for Herpes Zoster (Shingles) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Herpes Zoster (Shingles) - Pipeline by Astellas Pharma Inc., H2 2015
Herpes Zoster (Shingles) - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015
Herpes Zoster (Shingles) - Pipeline by Epiphany Biosciences, Inc., H2 2015
Herpes Zoster (Shingles) - Pipeline by Foamix Pharmaceuticals Ltd., H2 2015
Herpes Zoster (Shingles) - Pipeline by GlaxoSmithKline Plc, H2 2015
Herpes Zoster (Shingles) - Pipeline by Merck & Co., Inc., H2 2015
Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd., H2 2015
Herpes Zoster (Shingles) - Pipeline by Spider Biotech, H2 2015
Herpes Zoster (Shingles) - Pipeline by TSRL, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Herpes Zoster (Shingles) Therapeutics - Recent Pipeline Updates, H2 2015
Herpes Zoster (Shingles) - Dormant Projects, H2 2015
Herpes Zoster (Shingles) - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Herpes Zoster (Shingles), H2 2015
Number of Products under Development for Herpes Zoster (Shingles) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report